SCHEMBL565442

SCHEMBL565442

O=C(CCCCC1SC[C@@H]2NC(=O)N[C@H]12)Nc1ccc(C(=O)O)cc1.[NaH]

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 6/20 0.72
CA1 P00915 6/20 0.72
CA2 P00918 6/20 0.72
CA9 Q16790 6/20 0.72
PTPRF P10586 2/20 0.62
PTPN2 P17706 2/20 0.62
PTPN1 P18031 2/20 0.62
TDP1 Q9NUW8 5/20 0.61
PKM P14618 2/20 0.61
MEN1 O00255 1/20 0.61
ABL1 P00519 1/20 0.61
LMNA P02545 1/20 0.61
IDE P14735 1/20 0.61
MAPK1 P28482 1/20 0.61
KMT2A Q03164 1/20 0.61
RIN1 Q13671 1/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
SLC6A3 Q01959 2/20 0.57
ITGB1 P05556 1/20 0.53
ITGA4 P13612 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18391007 0.99 CA12 (0.73) CA12CA1CA2CA9PTPRF
SCHEMBL6036966 0.99 CA12 (0.73) CA12CA1CA2CA9PTPRF
SCHEMBL3620407 0.99 CA12 (0.73) CA12CA1CA2CA9PTPRF
SCHEMBL14253654 0.89 CA12 (0.74) CA12CA1CA2CA9PTPRF
SCHEMBL25374435 0.89 CA12 (0.74) CA12CA1CA2CA9PTPRF
SCHEMBL565441 0.89 CA12 (0.74) CA12CA1CA2CA9PTPRF
SCHEMBL19940249 0.87 CA12 (0.74) CA12CA1CA2CA9PTPRF
SCHEMBL21524959 0.87 CA12 (0.78) CA12CA1CA2CA9PTPRF
SCHEMBL18329586 0.87 CA12 (0.74) CA12CA1CA2CA9PTPRF
SCHEMBL12059002 0.87 CA12 (0.74) CA12CA1CA2CA9PTPRF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3391876-A1 LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL SDG, Inc. (US) 2018-10-24 EP disclosed
US-20120035105-A1 Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments SDG, INC. 2012-02-09 US disclosed
US-20110135725-A1 Lipid Construct for Delivery of Insulin to a Mammal SDG, INC. (US) 2011-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035105-A1 Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments IAPP, IDE, INSR CA12 4358/4885CA1 4861/4885CA2 3962/4885
US-20110135725-A1 Lipid Construct for Delivery of Insulin to a Mammal INSR, IAPP, GPR119 CA12 2944/4885CA1 2697/4885CA2 3633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.